Mounjaro and Libido
Based on current evidence, Mounjaro (tirzepatide) does not appear to directly cause decreased libido, and emerging data suggest it may actually reduce erectile dysfunction risk in men with type 2 diabetes. However, one case report documents sexual dysfunction in a woman taking tirzepatide, though causality remains uncertain.
Evidence for Men with Type 2 Diabetes
The most relevant recent evidence comes from a 2025 retrospective cohort study showing that tirzepatide was associated with significantly lower risk of erectile dysfunction compared to other diabetes medications 1. Specifically:
- 30% lower risk versus sitagliptin (RR 0.70,95% CI: 0.64-0.76)
- 33% lower risk versus injectable semaglutide (RR 0.67,95% CI: 0.62-0.72)
- 45% lower risk versus dulaglutide (RR 0.55,95% CI: 0.51-0.59)
This protective effect likely stems from tirzepatide's substantial metabolic benefits—weight loss of 15-20%, improved glycemic control, and cardiovascular risk factor reduction 2, 3—all of which independently improve erectile function in men with diabetes.
Isolated Case Report in Women
One 2025 case report described a 36-year-old woman who developed decreased sexual desire, genital dryness, and anorgasmia while taking tirzepatide (FSFI score dropped from 28.7 to 12.7) 4. Symptoms improved after discontinuation and recurred with rechallenge. However:
- This represents a single case without mechanistic explanation
- All hormonal and metabolic parameters remained normal
- The patient was simultaneously undergoing intensive lifestyle modification
- Causality cannot be definitively established from one case
What the FDA Label Says
The official Mounjaro prescribing information does not list libido changes or sexual dysfunction among documented adverse reactions 5. The most common side effects remain gastrointestinal (nausea 12-18%, diarrhea 12-17%, vomiting 5-9%).
Clinical Guidance
For men with type 2 diabetes: Reassure patients that tirzepatide appears more likely to improve rather than impair erectile function, likely through metabolic improvement and weight loss. The 2011 diabetes guidelines note that erectile dysfunction affects 35-90% of diabetic men and is strongly linked to poor glycemic control, obesity, and cardiovascular risk factors 6—all targets of tirzepatide therapy.
For women: While one case suggests possible sexual side effects, this is not an established pattern. If sexual dysfunction develops:
- Rule out other causes (hormonal, metabolic, psychological, relationship factors)
- Consider whether rapid weight loss itself may be contributing
- Weigh against substantial cardiometabolic benefits (22.5% weight loss at 15 mg dose) 3
- Trial discontinuation if symptoms are severe and temporally related
Common pitfall: Attributing all new symptoms to a recently started medication. Sexual dysfunction is multifactorial, particularly in patients with diabetes and obesity. The baseline prevalence is high—55% of men with type 1 diabetes report decreased libido even before treatment 6.
Mechanism Considerations
The protective effect in men likely operates through:
- Weight loss improving testosterone levels and vascular function
- Improved glycemic control reducing microvascular and autonomic neuropathy
- Cardiovascular risk reduction improving penile blood flow 6, 7
The proposed mechanism for the single female case remains speculative, with the authors suggesting possible effects on neurological pathways 4, though no hormonal changes were documented.